𝛼SK or Searchbullish
Hanmi Pharm (128940 KS/Buy)Roche’s Answer to Eli Lilly and Novo Nordisk
Our target price for Hanmi Pharm is based on an operating value estimate of W5.2tr and a pipeline value estimate of W4.3tr (vs. W3.1tr previously).
What is covered in the Full Insight:
- Overview of Hanmi Pharm's Licensing Deal
- Valuation Adjustments Post-Deal
- Competitive Position in the Obesity Market
- HM17321 Development and Potential
- Upcoming Clinical and Market Catalysts
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 20-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Hanmi Pharm (128940 KS/Buy)Roche’s Answer to Eli Lilly and Novo Nordisk28 Aug 2026
x